1091454437_Branded_med.jpg

IN THE NEWS

15 PITTSBURGH TECH COMPANIES TO WATCH IN 2021

Next Pittsburgh Jan 4, 2021

We checked in with experts in the tech sector and, based on our own knowledge, came up with our picks for the top tech companies to watch in 2021. Read More

NEWS RELEASE WOLF ADMINISTRATION HIGHLIGHTS DEVELOPMENT OF PROMISING NEW DRUG CANDIDATE TO TREAT COVID-19

DCED Dec 9, 2020

Today, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works CEO Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of a new COVID-19 treatment. Read More

HOW CYTOAGENTS’ PLANS FOR GROWTH RUN FAR BEYOND COVID CRISIS

Pittsburgh Business Times Dec 9, 2020

GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said. Read More

NEW COVID-19 TREATMENT SHOWS ENCOURAGING EARLY RESULTS, NORTH SHORE BIOTECH COMPANY SAYS

Pittsburgh Post-Gazette Dec 9, 2020

A North Shore biotech company is reporting encouraging early clinical results for a new COVID-19 treatment that targets the disease’s inflammatory process. Read More

CYTOAGENTS WORKING ON DRUG TO TREAT COVID-19

WJAC Dec 9, 2020

In a press conference Wednesday afternoon, the Department of Community and Economic Development introduced CytoAgents, a Ben Franklin Technology Partners company. Read More

PROMISING NEW TREATMENT

KDKA-TV | CBS Pittsburgh Dec 9, 2020

CytoAgents, based in Pittsburgh, says it is beginning its Phase 1 clinical trial for a new drug showing promise in the treatment of COVID-19. Read More

PITTSBURGH-BASED COMPANY BEHIND ‘PROMISING’ NEW COVID-19 TREATMENT

Pittsburgh Action News 4 Dec 9, 2020

On Wednesday, the Wolf Administration plans to highlight what it calls in a news advisory a “promising new drug candidate to treat COVID-19.” Read More

NEW DRUG DEVELOPED BY PITTSBURGH-BASED COMPANY SHOWING PROMISE IN TREATMENT OF COVID-19

KDKA-TV News Dec 9, 2020

A new drug developed by a Pittsburgh-based biotechnology company is showing promise in treating COVID-19. The Wolf Administration hosted a news conference Wednesday morning to announce the development of the new drug. Read More

INTERVIEW WITH TERESA WHALEN, CEO – OUR REGION'S BUSINESS ON WPXI-TV

Pittsburgh October 18, 2020

CytoAgents CEO, Teresa Whalen, RPh spoke with Bill Flanagan at WPXI-TV about our lead drug candidate GP1681 entering clinical trials. She discussed how GP1681 is designed to calm the "cytokine storm," a condition triggered by COVID-19, influenza, and other respiratory viruses. Often, the cytokine storm causes more damage then the viruses themselves.

NEWS RELEASE CYTOAGENTS LAUNCHES CLINICAL TRIALS FOR GP1681, TREATMENT OF COVID-19 CYTOKINE STORM

Pittsburgh October 13, 2020

CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead drug candidate, GP1681, for treatment of COVID-19 “cytokine storm,” clinically known as hypercytokinemia. Read More

NEWS RELEASE CYTOAGENTS RECEIVES FUNDING TO ACCELERATE COVID-19 CLINICAL TRIALS FOR CYTOKINE STORM TREATMENT FROM RICHARD KING MELLON FOUNDATION

Pittsburgh July 7, 2020

CytoAgents, a clinical-stage biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases, including COVID-19 and the resulting cytokine storm, announced today that it has received an investment to accelerate the development of its lead drug candidate, GP1681, an investigational new drug to treat “cytokine storm” induced by COVID-19, from the Richard King Mellon Foundation. Read More

CYTOAGENTS RECEIVES FUNDING TO ACCELERATE COVID-19 CLINICAL TRIALS FOR CYTOKINE STORM TREATMENT FROM RICHARD KING MELLON FOUNDATION

Yahoo Finance July 7, 2020

CYTOAGENTS GETS NIH FUNDING TO ADVANCE THERAPY FOR CYTOKINE STORM

Pharmaceutical Technology May 14, 2020

CYTOAGENTS RECEIVES NIH FUNDING TO ACCELERATE TREATMENT FOR CYTOKINE STORM

Boston Harbor Angels May 14, 2020

PITTSBURGH BIOTECH COMPANY RECEIVES $1.6 MILLION GRANT TO DEVELOP DRUG TO TREAT COVID-19

Pittsburgh Action News 4 May 14, 2020

NEWS RELEASE CYTOAGENTS RECEIVES NIH FUNDING TO ACCELERATE TREATMENT FOR CYTOKINE STORM

Pittsburgh May 13, 2020

CytoAgents, a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases, announced today that it has been awarded a National Institutes of Health (NIH) grant to accelerate the development of its lead drug candidate, GP1681, an investigational new drug to treat severe influenza, and potentially COVID-19, by targeting hypercytokinemia, more commonly known as “cytokine storm.” Read More

PITTSBURGH BIOTECH FIRM WINS NIH GRANT FOR COVID-19 CLINICAL TRIAL

Pittsburgh Business Times May 13, 2020

NORTH SHORE COMPANY GETS $1.6 MILLION GRANT FOR NEW DRUG DEVELOPMENT

Pittsburgh Post-Gazette May 13, 2020

PITTSBURGH HAS LONG BEEN A LIFE SCIENCES ENGINE. NOW IT’S AT THE FOREFRONT OF COVID-19 VACCINE EFFORTS

Technical.ly Media May 13, 2020

QUOTIENT SCIENCES, CYTOAGENTS FORM COVID-19 COLLABORATION

Contract Pharma May 4, 2020

NEWS RELEASE QUOTIENT SCIENCES AND CYTOAGENTS ACCELERATE POTENTIAL TREATMENT FOR COVID-19 CYTOKINE STORM

Nottingham, U.K., and Pittsburgh April 28, 2020

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases. Read More

© 2021 by CytoAgents

  • LI-In-Bug